Clinical trials: COPD Patients
COPD, Chronic Obstructive Pulmonary Disease
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
The Objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces…
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
- Trial name
- ASCENT COPD (NCT01966107)
- Testing
- Aclidinium Bromide
- Where
- 468 sites in United States, Canada
- Volunteers
- 3,635 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, COPD
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 \& 600 µg o.d.) in order to select two doses to carry forward into study Stage 2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00463567
- Testing
- Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.)
- Where
- 344 sites in United States, Argentina and 10 more
- Volunteers
- 2,059 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.
This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD.
- Trial name
- NCT00563381
- Testing
- Tiotropium bromide, Salmeterol
- Where
- 752 sites in Austria, Belgium and 23 more
- Volunteers
- 7,376 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and…
- Trial name
- FAST (NCT01922271)
- Testing
- NVA237, Tiotropium, Salbutamol
- Where
- 14 sites in Germany
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)
To test the effect of the research study drug, inhaled fluticasone on lung function in exercising patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00387036
- Testing
- Fluticasone
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Disease, Chronic Obstructive
Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg
The purpose of this study is to assess the control of COPD using a symptom and exacerbation risk based treatment strategy based on GOLD 2011.
- Trial name
- NCT01762800
- Testing
- fluticasone propionate/salmeterol 50/250mcg, tiotropium bromide 18mcg, fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg
- Where
- 39 sites in Japan
- Volunteers
- 407 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic
Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
When using the Breathe Technologies Ventilation System during simulated activities of daily living (ADLs), Subjects with moderate-to-severe chronic obstructive pulmonary Disease (COPD) will be comfortable and report acceptability.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
- Trial name
- PRIDE (NCT01355978)
- Testing
- Noninvasive Open Ventilation System
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Breathe Technologies, Inc.
Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01437540
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
- Where
- 137 sites in United States
- Volunteers
- 590 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary…
- Trial name
- GLOW6 (NCT01604278)
- Testing
- NVA237 50 µg and indacaterol 150 µg
- Where
- 80 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 449 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients
This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to…
- Trial name
- GLOW4 (NCT01119937)
- Testing
- NVA237, Tiotropium
- Where
- 40 sites in Japan
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Effects of Vibration Training on Exercise Capacity in COPD-patients
The aim of this study is to investigate the exercise capacity in COPD-patients performing a vibration training additional to a standard three-week rehabilitation program in comparison to patients performing merely a…
- Trial name
- NCT01380639
- Testing
- whole body vibration training
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Schön Klinik Berchtesgadener Land
Neuromuscular Blockade, Chronic Obstructive Pulmonary Disease
Comparison of Time to Extubation Using Sugammadex or Neostigmine
A prospective blinded randomized clinical trial to compare time to extubation using Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular blockade agents in an outpatient bronchoscopy suite.
- Trial name
- NCT04606901
- Testing
- neostigmine/glycopyrrolate, sugammadex
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Temple University
Dyspnea
Aerosol Inhalation Treatment for Dyspnea - Patients
The purpose of this protocol is to develop and test aerosol furosemide, as a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.
- Trial name
- NCT02524054
- Testing
- Furosemide, Aerosolized saline
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Obstructive Pulmonary Disease (COPD)
12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
In this 12-week study, patients were randomized to either open-label indacaterol or standard of care for Chronic Obstructive Pulmonary Disease (COPD) treatment; efficacy and safety were assessed.
- Trial name
- MOVE-ON (NCT01232894)
- Testing
- Indacaterol, Long-acting beta2-agonist
- Where
- 8 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat inhaler once daily for 4 weeks in Japanese patients with chronic obstructive pulmonary disease…
- Trial name
- NCT00824382
- Testing
- BI 1744 CL 2 µg, BI 1744 CL 5 µg, BI 1744 CL 10 µg
- Where
- 48 sites in Japan
- Volunteers
- 328 people
- Sponsor
- Boehringer Ingelheim
COPD Patients With Homogeneous Emphysema, Endoscopic Lung Volume Reduction With Endobronchial Valve
Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study
The aim of this prospective, randomized, controlled, one-way crossover study is to assess and compare the efficacy of the Zephyr endobronchial valves vs.
- Trial name
- IMPACT (NCT02025205)
- Testing
- Endobronchial Valve
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 93 people
- Sponsor
- Pulmonx International Sàrl
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST2 (NCT00877383)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 176 sites in United States, Canada and 7 more
- Volunteers
- 1,142 people
- Sponsor
- Novartis Pharmaceuticals
COPD, LUNG DISEASES, OBSTRUCTIVE
Airway Effects of Tiotropium in Patients With COPD
The aim of the study is to investigate the effect of tiotropium from different devices on a panel of small (IOS, MBNW, DLCO, FVC) and large airway (FEV1, PEF) responses in patients with mild-moderate COPD.
- Trial name
- NCT02683668
- Testing
- Handihaler-Tiotropium 18 mcg untrained, Handihaler-Tiotropium 18 mcg trained, Respimat-Tiotropium 5 mcg trained
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Imperial College London
Chronic Obstructive Pulmonary Disease, Lung Disease
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients with chronic obstructive pulmonary disease.
- Trial name
- NCT01215279
- Testing
- AZD2423
- Where
- 6 sites in Bulgaria, Slovakia
- Volunteers
- 63 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
The primary objective of this study is to demonstrate that treatment with a free combination of tiotropium and salmeterol provides superior improvement in static lung volumes and exercise tolerance compared to a fixed combination…
- Trial name
- NCT00530842
- Testing
- Tiotropium plus Salmeterol, Fluticasone/Salmeterol
- Where
- 42 sites in Austria, Canada and 5 more
- Volunteers
- 344 people
- Sponsor
- Boehringer Ingelheim